AurélieCamard

Counsel

Paris + 33.1.56.59.46.04

Connect:

Share

Aurélie Camard's practice focuses on private, domestic, and cross-border M&A transactions, advising French and foreign clients on acquisitions, divestments, mergers, carve-outs, strategic alliances, and joint ventures. Aurélie's practice also includes general corporate and contractual law matters.

Aurélie has represented clients in various industries for more than 10 years, notably in the energy, manufacturing, new technologies, health care, life sciences, and financial services sectors.

In the energy sector, Aurélie has advised TotalEnergies on several projects. She also regularly represents Sanofi, one of the French leading pharmaceutical companies, in the divestment of product portfolios.

In addition, Aurélie has significant experience in the defense, life sciences, and services sectors, advising clients on a wide range of M&A and corporate law matters.

Experience

  • Sanofi sells two established product portfolios to NeuraxpharmJones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm.
  • Électricité de Strasbourg forms JV with ErametJones Day advised Électricité de Strasbourg, an energy provider in Alsace (France), in the formation of a joint venture with Eramet, one of the leading French actors in the mining and metallurgy industries, to develop and use joint capabilities for the extraction, refining and production of lithium from geothermal resources, with a targeted annual volume of 10,000 tons of lithium corresponding to the volume necessary to produce c.250,000 batteries for electric vehicles per year).
  • Timken acquires GGB Bearing Technology for $305 millionJones Day advised The Timken Company in the $305 million acquisition of GGB Bearing Technology (GGB), a division of Enpro, Industries (including exclusive negotiations with respect to the French operations of GGB).
  • Diebold Nixdorf successfully restructures over $2.7 billion in funded debt and completes the first-ever dual proceeding under the U.S. bankruptcy code and Dutch restructuring law in 71 daysIn the first-ever cross border restructuring involving dual main proceedings under chapter 11 of the U.S. Bankruptcy Code and a scheme of arrangement (the "Dutch Scheme") under the Dutch Act on Confirmation of Extrajudicial Plans (Wet Homologatie Onderhands Akkoord ("WHOA")), and the first-ever chapter 15 recognition of Dutch Scheme proceedings and a sanctioned WHOA reorganization plan (the "WHOA Plan"), Jones Day represented Diebold Nixdorf, Incorporated ("Diebold") and certain of its U.S. and Canadian subsidiaries (the "Debtors") in connection with (i) the prepackaged chapter 11 cases of In re Diebold Holding Company, LLC, et al., (Case No. 23-90602-DRJ) commenced on June 1, 2023, in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"); (ii) the Dutch Scheme, commenced on June 1, 2023 by Diebold Nixdorf Dutch Holding B.V. (the "Dutch Issuer") in the District Court of Amsterdam (the "Dutch Court"), and (iii) the chapter 15 proceedings before the Bankruptcy Court commenced by the foreign representative of the Dutch Issuer, wherein the Bankruptcy Court recognized the Dutch Scheme proceeding as a foreign main proceeding and recognized and extended comity to the WHOA Plan that was sanctioned by the Dutch Court.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.